Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Key Takeaway: Gossamer Bio has appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026. Ciongoli will also be a member of the Audit Committee. This appointment is expected to enhance the company's leadership and governance as it focuses on developing treatments for pulmonary arterial hypertension and related conditions.
Price reaction · baseline $10.96 (2026-09-16 close) · hit after-hours · clean, no other GOSS news in the window
day 0 close · peak
+8.9%
day 1
-2.1%
day 3
+6.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Greg Ciongoli enhances leadership team.
  • Ciongoli brings valuable experience to the Board.
  • Strengthens Gossamer Bio's governance with new expertise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
17.4%
average across 6 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
Seralutinib
Phase 3 · Pulmonary Arterial Hypertension

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.
Mr. Ciongoli has served as the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, since April 2024. Prior to Adiumentum, he was a Partner at the Baupost Group, where he worked on a broad range of public and private equity investments. Mr. Ciongoli also serves on the boards of directors of REGENXBIO Inc., Zymeworks, Inc. and Atara Biotherapeutics, Inc. He is actively involved in a number of local not-for-profit organizations. Mr. Ciongoli graduated from Princeton University with an A.B. and received his M.B.A. from Harvard Business School.
“We are pleased to welcome Greg to our Board,” said Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio. “His deep investment experience and perspective on value creation will be an asset as we advance seralutinib toward a potential FDA approval and work to bring a new treatment option to patients with pulmonary hypertension.”
“I am excited to join the Gossamer Bio Board at such an important time for the Company,” said Mr. Ciongoli. “Seralutinib represents a compelling opportunity to address a serious unmet need, and I look forward to supporting the team as it advances the program.”

About Gossamer Bio

Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

Forward-Looking Statements

Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such statements include, but are not limited to, statements regarding advancing seralutinib toward a potential FDA approval and working to bring a new treatment option to patients with pulmonary hypertension. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer's business, and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company's annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

For Investors and Media: Bryan Giraudo, Chief Financial Officer & Chief Operating Officer Gossamer Bio Investor Relations ir@gossamerbio.com

Frequently Asked Questions

Who has been appointed to Gossamer Bio's Board?

Greg Ciongoli has been appointed to Gossamer Bio's Board of Directors.

When does Greg Ciongoli's appointment take effect?

His appointment takes effect on September 16, 2026.

What committee will Ciongoli serve on?

Ciongoli will serve as a member of the Audit Committee.

What is Gossamer Bio focused on developing?

Gossamer Bio focuses on treatments for pulmonary arterial hypertension and related conditions.

Last updated: Sep 16, 2026